Literature DB >> 26262451

The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer.

Mandy Man-Yee Chu1, Stephanie Si Liu, Kar-Fai Tam, Philip Pun-Ching Ip, Annie Nga-Yin Cheung, Hextan Yuen-Sheung Ngan.   

Abstract

The objective of this study was to identify the tumor characteristics associated with mismatch repair deficiency in young patients with endometrial carcinoma. Young patients (45 yr old or younger) with endometrial carcinoma treated by hysterectomy in our institution between July 2001 and June 2009 were identified. The clinical and pathologic data were obtained by review of clinical records. Among the 122 cases identified, paraffin sections were available in 67 cases for immunohistochemical staining and frozen tissue available in 62 cases for microsatellite instability (MSI) analysis. Both paraffin sections and frozen tissue were available in 36 cases. Among the 67 cases with immunohistochemical staining, 22 (32.8%) showed loss of expression of at least 1 mismatch repair protein. Defective MLH1 or MSH2 expression was associated with poor prognostic factors, including a higher incidence of pelvic lymph nodes metastasis (P=0.018) and higher stage (P=0.022) for MLH1, and an increased risk of lymphovascular permeation (P=0.015) for MSH2. On the contrary, defective MSH6 protein expression was associated with a lower incidence of high-grade tumors (P=0.04). Among the 62 cases with MSI analysis, 12 (19.4%) tumors were classified as microsatellite-high (MSI-H), whereas 2 (3.2%) were classified as microsatellite-low (MSI-L). There was no difference in the pathologic characteristics between MSI-stable and MSI-H tumor. We concluded that defective mismatch repair expression is important in young patients with endometrial carcinoma, with MSH6 protein being most commonly affected. The phenotype resulting from defective MSH6 expression was different from that caused by MLH1 or MSH2 loss.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26262451     DOI: 10.1097/PGP.0000000000000174

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  5 in total

1.  p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.

Authors:  Oluwole Fadare; Vinita Parkash
Journal:  Diagn Pathol       Date:  2017-11-14       Impact factor: 2.644

2.  Incomplete Segregation of MSH6 Frameshift Variants with Phenotype of Lynch Syndrome.

Authors:  Raffaella Liccardo; Marina De Rosa; Giovanni Battista Rossi; Nicola Carlomagno; Paola Izzo; Francesca Duraturo
Journal:  Int J Mol Sci       Date:  2017-05-06       Impact factor: 5.923

3.  The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis.

Authors:  N A J Ryan; M A Glaire; D Blake; M Cabrera-Dandy; D G Evans; E J Crosbie
Journal:  Genet Med       Date:  2019-05-14       Impact factor: 8.822

4.  A Model to Identify Candidates for Lymph Node Dissection Among Patients With High-Risk Endometrial Endometrioid Carcinoma According to Mayo Criteria.

Authors:  Wen Lu; Xiaoyue Chen; Jingyi Ni; Zhen Li; Tao Su; Shuangdi Li; Xiaoping Wan
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

Review 5.  The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review.

Authors:  Amelia Favier; Justine Varinot; Catherine Uzan; Alex Duval; Isabelle Brocheriou; Geoffroy Canlorbe
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.